Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

0%

0 of 6 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
3(50.0%)
Phase 1
2(33.3%)
Phase 3
1(16.7%)
6Total
Phase 2(3)
Phase 1(2)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT01734408Phase 2Completed

A Booster Dose of Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children

Role: collaborator

NCT01679665Phase 2Completed

Systems Biology of Vaccination for EV71 Vaccine in Humans

Role: collaborator

NCT01508247Phase 3Completed

A Clinical Trial to Assess the Efficacy and Safety of an Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children Aged 6-35 Months

Role: collaborator

NCT01399853Phase 2Completed

A Phase II Clinical Trial for Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children and Infants

Role: collaborator

NCT01313715Phase 1Completed

A Clinical Trial for Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children and Infants

Role: collaborator

NCT01267903Phase 1Completed

A Clinical Trial for Inactivated Vaccine(Vero Cell) Against EV71 in Chinese Healthy Young Adults and Children

Role: collaborator

All 6 trials loaded